Drug intelligence / Profile preview

AD-218

Development stage: Phase 3
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-218 is an oral small molecule drug candidate developed by Addpharma for the treatment of mixed dyslipidemia and other dyslipidemias. It is currently in Phase 3 clinical trials, primarily in Korea. The precise mechanism of action remains unknown. There are no known adverse events reported so far, and the drug has not received any regulatory approval or special FDA designation.

Beyond the preview

Go deeper on AD-218.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-218.

Explore the full profile